...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Open access Rheumatology: Research and Reviews >The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life
【24h】

The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life

机译：塞妥珠单抗（CZP）治疗类风湿关节炎的临床疗效和安全性：长期使用，患者注意事项以及对生活质量的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: Rheumatoid arthritis can cause chronic pain, disability, fatigue and loss of productivity both in the workplace and at home. Fatigue, not joint pain, swelling or that there may be radiographic damage, is frequently mentioned by patients as their most debilitating problem. In the era prior to biologic therapy in rheumatoid arthritis, it was reported that 40% to 50% of individuals reported work loss within 10 years of the onset of their disease. Rheumatoid arthritis is not just associated with chronic pain and inability to function normally; there is a significant economic burden caused by the disease which affects society as well the individual. Work disability in individuals with rheumatoid arthritis occurs early and increases over time. Early, aggressive treatment has now become the norm in clinical practice with changes of medication dictated by measuring the presence of continued disease activity. The combination of adequately dosed methotrexate and a biologic agent, especially a TNFα inhibitor, has been shown to be far more effective than traditional disease modifying anti-rheumatic drugs in early and long-standing disease, with respect to clinical, radiologic and functional outcomes. Unfortunately, not all patients respond to all medications equally; indeed a patient may fail a number of medications, either alone or in combination, and then respond to another medication. For this reason, there is room in our therapeutic armamentarium for additional effective agents such as certolizumab pegol. The results of up to 100 weeks of treatment with certolizumab pegol with an emphasis on functional outcomes, is the focus of this review.
机译：摘要：类风湿关节炎可在工作场所和家庭中引起慢性疼痛，残疾，疲劳和生产力下降。患者经常提到疲劳，而不是关节疼痛，肿胀或可能的射线照相损伤，是他们最使人衰弱的问题。在风湿性关节炎的生物治疗之前的时代，据报道有40％至50％的人在疾病发作后的10年内报告失去工作。类风湿关节炎不仅与慢性疼痛和无法正常工作有关;这种疾病造成了巨大的经济负担，影响了社会和个人。类风湿性关节炎患者的工作障碍较早发生，并随着时间的推移而增加。早期，积极的治疗现已成为临床实践中的常态，通过测量持续疾病活动的存在来决定药物的变化。就临床，放射学和功能结局而言，在早期和长期疾病中，足量甲氨蝶呤和生物制剂（尤其是TNFα抑制剂）的结合已被证明比传统的抗风湿药物更有效。不幸的是，并非所有患者对所有药物的反应均等。实际上，患者可能会单独或联合使用多种药物而失败，然后对另一种药物产生反应。因此，我们的治疗药房中还有其他有效药剂（例如塞妥珠单抗聚乙二醇化乙二醇）的空间。本评价的重点是使用西妥珠单抗聚乙二醇酯长达100周的治疗结果，重点是功能结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号